You are here: Industry Insights > InnoCare

News List

InnoCare Sets up Specific Environment Management Target in its Fifth ESG Report PharmaSources
April 28, 2024
InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases.
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib PharmaSources
April 01, 2024
ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, developed by InnoCare for the treatment of solid tumors as a single agent and/or in combination with other antitumor agents.
InnoCare Releases 2023 Results and Business Highlights PharmaSources
March 29, 2024
InnoCare Pharma, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.
InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China PharmaSources
January 24, 2024
Jan. 24, 2024 - InnoCare Pharma announced today that the first pediatric patient has been dosed in clinical trial with its second.
InnoCare Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA PharmaSources
January 16, 2024
ICP-248 is a novel, orally bioavailable BCL2-selective inhibitor, which aims to treat hematologic malignancies as a monotherapy or in combination with other therapies.
InnoCare and Keymed Jointly Announce First Subject Dosed in Clinical Trial of CCR8 Monoclonal Antibody ICP-B05 PharmaSources
February 24, 2023
InnoCare Pharma and Keymed Biosciences that the first subject has been dosed in clinical trial of ICP-B05.
Chinese BTK Inhibitor Orelabrutinib Gone Global, What Other Drugs Have Been Ok'd Overseas in 2021 PharmaSources/Dopine
July 26, 2021
On July 13, InnoCare Pharma and Biogen made joint announcement that they have entered into an agreement on the license and cooperation of the BTK inhibitor Orelabrutinib.
InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China PharmaSources
November 15, 2024
InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China
InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet Primary Endpoint in Psoriasis Patients PharmaSources
October 10, 2024
InnoCare Pharma announced today that phase II clinical study results of novel TYK2 (Tyrosine Kinase 2) inhibitor ICP-488 met the primary endpoint in adult patients with moderate-to-severe plaque psoriasis.
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China PharmaSources
September 19, 2024
InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Previous page 1 2 3 4 5 6 7 Next page